- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.01. | On biotech's biggest stage, renewed excitement gets a stress test | ||
| 15.01. | Trump unveils healthcare affordability plan | ||
| 15.01. | Tecvayli tops standard drugs in early multiple myeloma, J&J says | ||
| 15.01. | Oxford Biomedica confirms takeover talks with biotech investor EQT | ||
| 15.01. | Boston Scientific to acquire Penumbra for $14.5B | ||
| 14.01. | JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma's cell therapy view | ||
| 14.01. | Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill | ||
| 14.01. | Caldera starts up with $112.5M and a dual-targeting immune drug from China | ||
| 13.01. | JPM26: Biotech's M&A lift, the 'new' Biogen and Merck's $70B target | ||
| 13.01. | Digital health funding increases in 2025, spurred by AI: report | ||
| 13.01. | What Sanofi's multiple sclerosis troubles could mean for the space | ||
| 13.01. | AbbVie pledges $100B to US production in drug pricing deal with Trump | ||
| 12.01. | JPM26: US biotech's 'Sputnik moment,' Pfizer's obesity ambitions and Bristol Myers' big year | ||
| 12.01. | AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations | ||
| 12.01. | Best practices for COA selection: Building a stronger foundation for clinical trials | ||
| 12.01. | Building more sustainable cold chain packaging through innovation | ||
| 12.01. | 5 questions facing biopharma in 2026 | ||
| 09.01. | Insmed's 'ginormous' lung drug sales; J&J's US pricing deal | ||
| 09.01. | Aurora sets out to capitalize on FDA's new framework for bespoke drug therapies | ||
| 08.01. | Alveus launches with $160M to advance MariTide-like obesity drug | ||
| 08.01. | Parabilis, chasing 'undruggable' targets, nabs $305M amid VC funding blitz | ||
| 08.01. | Diagonal banks another $125M for 'clustering' antibody drugs | ||
| 08.01. | EpiBiologics raises $107M for its protein-degrading cancer drug | ||
| 07.01. | Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs | ||
| 07.01. | GSK, Ionis claim study success for RNA-based hepatitis B drug |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.